Stallergenes Greer

House dust mites

Biotech

Stallergenes' allergy immunotherapy hits goal in phase 3

The late-phase success sets Stallergenes up to file for FDA approval of oral immunotherapy STAGR320.

Nick Paul Taylor Nov 20, 2018 9:00am

Pact

Stallergenes, Stanford pen allergy immunotherapy pact

Nov 14, 2016 5:51am

Stairs

Stallergenes Greer poaches Zoetis IT exec following manufacturing mixup

Apr 15, 2016 2:32am